Menü
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

ICON Issues Financial Guidance for Full Year 2020
ICON Issues Financial Guidance for Full Year 2020


ICON plc (NASDAQ: ICLR), global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200113005846/en/



(Photo: Business Wire)




Ipsen (Euronext: IPN; ADR

Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020


Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.



On the same day, at

QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer
QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510

QIAGEN erweitert globale Zusammenarbeit mit Amgen zur Entwicklung von Begleitdiagnostika bei nicht-kleinzelligem Lungenkrebs
QIAGEN erweitert globale Zusammenarbeit mit Amgen zur Entwicklung von Begleitdiagnostika bei nicht-kleinzelligem Lungenkrebs


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute eine strategische Zusammenarbeit zur Entwicklung von gewebebasierten Begleitdiagnostika für Amgens Krebsmedikament AMG 510 bekannt

MEDICREA Announces Preliminary Discussions With U.S. Strategic Partners
MEDICREA Announces Preliminary Discussions With U.S. Strategic Partners


The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market – MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics


Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership

Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing


Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year

Biofrontera: Es ist wieder Musik in der Aktie
Biofrontera: Es ist wieder Musik in der Aktie

Die Biofrontera-Aktie (WKN: 604611) bewegt sich am Montag explosionsartig über die 5-Euro-Marke. Besser als erwartete Umsatzzahlen für 2019 locken Anleger in den deutschen Pharma-Qualitätstitel.

Lantheus Holdings Announces Senior Leadership Appointment
Lantheus Holdings Announces Senior Leadership Appointment


Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative

ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020


ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates


Charles River (NYSE: CRL) today announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Together, Charles River and Takeda will launch multiple

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday

Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan

Waters to Acquire Andrew Alliance
Waters to Acquire Andrew Alliance


Waters Corporation (NYSE:WAT) announced today that it has entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including

Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook


DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be

Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering


Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring

Novus Therapeutics Provides Update on OP0201
Novus Therapeutics Provides Update on OP0201


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the

Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update


Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2019. Novocure plans to discuss these

Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys: Milliarden für Anti-Krebs-Blockbuster

Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip

NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019
NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today provided preliminary operational and financial results for the fourth quarter

Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the

Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein


Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch

Veeva to Present at the 38th Annual J.P. Morgan Healthcare Conference
Veeva to Present at the 38th Annual J.P. Morgan Healthcare Conference


Veeva Systems (NYSE:VEEV) today announced that Paul Shawah, SVP of Veeva Commercial Cloud, will present at the 38th annual J.P. Morgan Healthcare Conference on Thursday, Jan 16, 2020, at 10:00 a.m

Medigene: Gewaltige Kursgewinne nach super Daten!
Medigene: Gewaltige Kursgewinne nach super Daten!

Positive Studienergebnisse beflügeln die Aktien von Medigene (WKN: A1X3W0). Auf Xetra geht der Biotech-Wert mit einem Tagesplus von +33,35% auf 5,55 Euro aus dem Handel. Auf Tradegate steigt der